Breaking News Instant updates and real-time market news.

ONCS

OncoSec

$3.95

0.149 (3.92%)

08:36
05/22/19
05/22
08:36
05/22/19
08:36

OncoSec reports interim data from Keynote-890 study of breast cancer combination

OncoSec announced interim data from Keynote-890, an ongoing Phase 2 study of Tavo - intratumoral IL-12 - in combination with Keytruda in patients with heavily pretreated, metastatic, chemotherapy refractory triple negative breast cancer, or mTNBC. Patients who previously failed an average of 3.5 prior lines of chemotherapy were enrolled in Keynote-890 to evaluate if the addition of Tavo could provide meaningful clinical activity when combined with Keytruda. Heavily pretreated patients with refractory mTNBC showed a rapid tumor reduction of 20% or greater at the initial 3-month evaluation in the first five of 10 patients. Two patients had a partial response, one with a 66% tumor reduction, including a significant reduction of liver lesions, and four patients had stable disease, three of which reported a 20% or greater tumor reduction. These preliminary findings, when compared to the results of Keynote-086, which demonstrated a 5.3% response rate in mTNBC patients treated with Keytruda monotherapy, suggest Tavo's ability to unlock Keytruda's potential anti-cancer efficacy in this patient population. Four of the six patients who experienced tumor reductions have an ongoing response as of May 9. Of the four patients who progressed following treatment, two received only one cycle of combination treatment prior to rapid clinical deterioration. Treatment was very well-tolerated, with only three patients reporting Grade 1 Tavo-related adverse events. No Tavo-related Grade 2 or above AE's/SAE's were reported. The company has enrolled over half of the targeted enrollment of 25 patients, and expects to complete enrollment and present the clinical data at the San Antonio Breast Cancer Symposium later this year.

  • 22

    May

ONCS OncoSec
$3.95

0.149 (3.92%)

11/06/18
PIPR
11/06/18
NO CHANGE
Target $3
PIPR
Overweight
OncoSec price target lowered to $3 from $5 at Piper Jaffray
After OncoSec (ONCS) reported preliminary Phase 2b KEYNOTE-695 data for Tavo combined with Merck's (MRK) Keytruda in PD-1 refractory melanoma patients, Piper Jaffray analyst Edward Tenthoff said the data, while early, show evidence of clinical activity, adding that he believes duration of response data will be important. However, OncoSec shares are down 52% today, which Tenthoff attributes to the lower response rate compared to prior data in different patients. The analyst keeps an Overweight rating on OncoSec shares, but lowered his price target on the stock to $3 from $5 as he pushed out his approval projections for Tavo by one year in the U.S. and Europe.
11/07/18
HCWC
11/07/18
DOWNGRADE
Target $1
HCWC
Neutral
OncoSec downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju downgraded OncoSec to Neutral from Buy after the company reported preliminary top-line data from the PISCES/KEYNOTE-695 trial of TAVO with Keytruda in metastatic melanoma patients who have failed anti-PD-1 therapy, stating that his first impression is that the early efficacy results are "underwhelming." He noted that other second generation I/O agents have demonstrated higher response rates and while TAVO may eventually obtain regulatory approval, its efficacy may not be differentiated enough for wide market adoption. Selvaraju lowered his price target on OncoSec shares to $1 from $4.
12/12/18
PIPR
12/12/18
NO CHANGE
Target $3
PIPR
Overweight
Piper reiterates Overweight, $3 target on OncoSec after data
Piper Jaffray analyst Edward Tenthoff believes OncoSec Medical's updated six-month response data from the Phase IIb Keynote-695 data of tavo plus Keytruda in PD-1 refractory melanoma demonstrate tavo's ability to deepen tumor response over time. The analyst reiterates an Overweight rating on OncoSec with a $3 price target.
02/01/19
PIPR
02/01/19
NO CHANGE
Target $3
PIPR
Overweight
Piper says OncoSec's TAVO resensitizing anti-PD-1 progressers 'impressive'
After OncoSec (ONCS) reported updated data for the registrational KEYNOTE-695 study evaluating TAVO plus Merck's (MRK) Keytruda, Piper Jaffray analyst Edward Tenthoff noted that TAVO's ORR improved and called the fact that TAVO resensitized anti-PD-1 progressers "impressive." He reiterates an Overweight and $3 price target on OncoSec shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.